Skip to main content

Can Wegovy or Ozempic be used for heart failure?

Medically reviewed by Melisa Puckey, BPharm. Last updated on Jan 22, 2025.

Official Answer by Drugs.com

Can Wegovy or Ozempic (semaglutide) be used for heart failure?

Yes, Wegovy and Ozempic active ingredient semaglutide has been used for heart failure to improve heart failure symptoms, increase exercise function, and weight loss, in a clinical trial called STEP-HFpE (NCT04788511). The clinical trial used Wegovy and Ozempic’s active ingredient, semaglutide, in patients with heart failure with preserved ejection fraction and obesity compared to placebo treatment, over 52 weeks.

The goal of treating heart failure is to slow disease progression (hospitalization and death) and to improve patients' quality of life including their symptoms and ability to move or exercise.

Benefits of Wegovy and Ozempic for heart failure patients with obesity

*The Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) assesses symptoms of heart failure, physical and social limitations, and overall quality of life. Scores range from 0 to 100, where higher scores indicate fewer symptoms and reduced physical limitations.

Wegovy and Ozempic (semaglutide) are currently not FDA approved for heart failure.

Heart failure with obesity

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure where the heart maintains a normal or near-normal ejection fraction (LVEF is ≥50%). This type of heart failure is a condition that often occurs in individuals who have higher body weights. Patients with this type of heart failure and obesity have more clinical problems, greater symptoms, and impaired quality of life compared to patients with heart failure with preserved ejection fraction but no obesity.

By reducing body weight in obese HFpEF patients helps to reduce symptoms as HFpEF patients with lower body weight have less symptoms.

Related questions

How does Wegovy and Ozempic improve heart failure?

Wegovy and Ozempic improves heart failure with preserved ejection fraction (HFpEF) in obese patients by aiding weight loss. Semaglutide is a glucagon-like peptide 1 (GLP-1) agonist that works by mimicking a natural hormone in the body called GLP-1 which:

Summary

References

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. Accessed January 22, 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2306963

Wegovy Package Insert FDA. Accessed January 22, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s015lbl.pdf

Ozempic Package Insert FDA. Accessed January 22, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209637s032lbl.pdf

National Library of Medicine Heart failure with preserved ejection fraction. Accessed January 22, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC6334030/#S0001

Read next

Tirzepatide vs semaglutide: How do they compare?

Both tirzepatide and semaglutide are prescription medicines used with diet and exercise to treat people with type 2 diabetes or to help people lose and maintain weight loss. Tirzepatide is also approved by the FDA to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity, while semaglutide is approved to reduce the risk of serious heart problems and to help reduce the risk of worsening kidney disease.

Continue reading

Can you get tirzepatide from a compounding pharmacy?

Tirzepatide cannot be legally compounded in a U.S. pharmacy at this time. It has been removed from the FDA drug shortage list as of October 2, 2024. When drugs are in short supply, the FDA may allow temporary compounding of some medicines to allow patients to continue to access their treatments. Tirzepatide is now widely available as a prescription medicine made by Eli Lilly under the brands names Mounjaro (for type 2 diabetes) and Zepbound (for weight loss and sleep apnea).

Continue reading

Why am I not losing weight on Ozempic?

Although Ozempic is not FDA-approved for weight loss, over 86% of people lose at least 5% of their body weight in trials that have studied semaglutide, the active ingredient of Ozempic. But the same clinical trials also show that just under 14% don’t lose weight, and some may even gain weight. Continue reading

See also:

Related medical questions

Drug information

Related support groups